Remyelination in THREE animal models?
Posted: Fri Jan 19, 2007 6:36 am
I've just seen this on 'Acorda's' website, under "pipeline/R&d". It mentions three different animal models of MS, but I've only ever heard of EAE. Can anyone enlighten me on this?
Dom.
" Acorda’s remyelination programs include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath Myelin is the insulating layer of membranes that surrounds most nerve fibers. When an axon is demyelinated, nerve impulses “short circuit” much like a wire whose insulation has been stripped.
What is Demyelination?
In 2002, Acorda acquired an exclusive worldwide license from CeNeS, Ltd. to the neuregulins – a class of naturally occurring protein growth factors that have multiple effects on the nervous system and potential therapeutic applications in neurologic conditions.
The most clinically advanced of these agents, Glial Growth Factor 2 (GGF2), is a member of the neuregulin family of growth factors related to epidermal growth factor. The neuregulins bind to erbB receptors, which translate the growth factor signal to the cell and cause changes in cell growth, protein production and gene expression. The molecule was shown in published studies to stimulate remyelination in animal models of MS and to have a range of other effects in neural protection and repair.
Acorda’s remyelinating antibody program is based on an exclusive license to patents derived from more than 15 years of research performed at the Mayo Clinic. The program is designed to promote remyelination of affected areas of the brain and spinal cord.
Studies have demonstrated the ability of this family of antibodies to stimulate repair of the myelin sheath in three different animal models of MS. In particular, these antibodies were found to react with molecules on the surface of the cells that make the myelin sheath and stimulate them in a number of ways, leading to increased remyelination activity. First identified in mice, similar antibodies were subsequently identified in human blood samples by the Mayo team and Acorda has been able to produce a recombinant human antibody that may be suitable for clinical development.
Whereas Fampridine-SR may restore function by pharmacologically compensating for myelin loss in some axons, these antibodies may actually replace the lost myelin, which may provide additional benefit."
Dom.
" Acorda’s remyelination programs include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath Myelin is the insulating layer of membranes that surrounds most nerve fibers. When an axon is demyelinated, nerve impulses “short circuit” much like a wire whose insulation has been stripped.
What is Demyelination?
In 2002, Acorda acquired an exclusive worldwide license from CeNeS, Ltd. to the neuregulins – a class of naturally occurring protein growth factors that have multiple effects on the nervous system and potential therapeutic applications in neurologic conditions.
The most clinically advanced of these agents, Glial Growth Factor 2 (GGF2), is a member of the neuregulin family of growth factors related to epidermal growth factor. The neuregulins bind to erbB receptors, which translate the growth factor signal to the cell and cause changes in cell growth, protein production and gene expression. The molecule was shown in published studies to stimulate remyelination in animal models of MS and to have a range of other effects in neural protection and repair.
Acorda’s remyelinating antibody program is based on an exclusive license to patents derived from more than 15 years of research performed at the Mayo Clinic. The program is designed to promote remyelination of affected areas of the brain and spinal cord.
Studies have demonstrated the ability of this family of antibodies to stimulate repair of the myelin sheath in three different animal models of MS. In particular, these antibodies were found to react with molecules on the surface of the cells that make the myelin sheath and stimulate them in a number of ways, leading to increased remyelination activity. First identified in mice, similar antibodies were subsequently identified in human blood samples by the Mayo team and Acorda has been able to produce a recombinant human antibody that may be suitable for clinical development.
Whereas Fampridine-SR may restore function by pharmacologically compensating for myelin loss in some axons, these antibodies may actually replace the lost myelin, which may provide additional benefit."